Ipsen, Genfit Medicine Is Cleared by FDA for Rare Liver Disorder

Ipsen SA and partner Genfit SA won US regulators’ clearance for the first new treatment option in eight years for patients with a rare liver disease.

The US Food and Drug Administration approved the medicine, elafibranor, for adults with primary biliary cholangitis, an autoimmune disease in which the bile ducts become inflamed and slowly destroyed. The drug will be called Iqirvo, Ipsen said in a statement Monday.